☆ 4.5 Article

Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes

VACCINE (2023)

Related references

Note: Only part of the references are listed.

Article Multidisciplinary Sciences

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Juan Manuel Carreno et al.

Summary: The Omicron variant of SARS-CoV-2, first identified in South Africa and Botswana in November 2021, has rapidly spread globally with high transmissibility. It has an unprecedented number of mutations in its spike gene, leading to immune escape and reduced vaccine efficacy. The neutralizing and binding activity against Omicron varies among individuals with different vaccination and infection histories.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Sandile Cele et al.

Summary: The study found that the Omicron variant has reduced neutralizing effectiveness in individuals vaccinated with Pfizer BNT162b2, but those who had previously been infected with SARS-CoV-2 showed better neutralization against Omicron.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Yunlong Cao et al.

Summary: The Omicron variant of SARS-CoV-2 contains 15 mutations in the receptor-binding domain, leading to evasion of over 85% of tested neutralizing antibodies. Different epitope groups of neutralizing antibodies are affected to varying degrees by single mutations of Omicron. Antibodies targeting the conserved region of sarbecovirus remain most effective against Omicron.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Lihong Liu et al.

Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.

NATURE (2022)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons

Annika Roessler et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants

Ruediger Gross et al.

Summary: According to a study on a cohort of individuals who received heterologous ChAdOx1 nCoV-19 BNT162b2 vaccination, the regimen induced potent humoral and cellular immune responses, with strong neutralization of the most prevalent SARS-CoV-2 variants. The results suggest that this heterologous vaccination regimen is at least as immunogenic and protective as homologous vaccinations and also offers protection against current variants of concern.

EBIOMEDICINE (2022)

Add to Collection

Letter Immunology

Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Chloe Dimeglio et al.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Letter Medicine, General & Internal

Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection

Annika Roessler et al.

Summary: Although some antibodies generated in persons recovering from infection with the omicron variant show cross-reactivity, a group of unvaccinated individuals were found to have largely ineffective antibodies against other viral strains.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2

Eduardo Hermosilla et al.

Summary: A cohort analysis from Catalonia shows that heterologous vaccination with ChAdOx1 followed by BNT162b2 has better vaccine effectiveness than two doses of ChAdOx1.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Medicine, General & Internal

Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial

Zoltan Banki et al.

Summary: This study demonstrates the immunogenicity and safety of heterologous AZ/BNT vaccination, which is superior to homologous AZ/AZ vaccination, encouraging further research on heterologous vaccination schedules.

EBIOMEDICINE (2022)

Add to Collection

Review Biochemistry & Molecular Biology

COVID-19 vaccines: where we stand and challenges ahead

Guido Forni et al.

Summary: The development of vaccines has made significant progress, but still faces various challenges, including different target populations, immunological adaptability of vaccines, and production and distribution issues. To ensure equitable access, protection of diverse subjects, and immunity against viral variants, multiple vaccines may be needed in the long run.

CELL DEATH AND DIFFERENTIATION (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination

Bruno Pozzetto et al.

Summary: The study found that a heterologous vaccination regimen using ChAdOx1-S-nCoV-19 and BNT162b2 can provide better protection against SARS-CoV-2 infection with stronger neutralizing activity. This approach can activate memory B cells that recognize SARS-CoV-2, making it suitable for immunocompromised individuals.

NATURE (2021)

Add to Collection

Article Medicine, General & Internal

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey et al.

Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.

LANCET (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Letter Pharmacology & Pharmacy

Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres

Valerie Gras-Champel et al.

THERAPIE (2021)

Add to Collection

Article Infectious Diseases

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England

Annabel A. Powell et al.

Summary: Adults receiving heterologous COVID-19 immunisation with mRNA or adenoviral-vector vaccines had higher reactogenicity rates, especially among those aged over 50, women, and individuals with prior symptomatic/confirmed COVID-19. Those who received heterologous schedules after severe first-dose reactions may have lower reactogenicity after the second dose, depending on the specific combination of vaccines used.

EUROSURVEILLANCE (2021)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Xinxue Liu et al.

Summary: Heterologous prime-boost COVID-19 vaccine schedules could facilitate mass immunisation, with ChAd/BNT showing non-inferior immunogenicity compared to ChAd/ChAd, but BNT/ChAd did not demonstrate non-inferiority to BNT/BNT. The results support flexibility in using heterologous prime-boost vaccination with ChAd and BNT COVID-19 vaccines.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia et al.

Summary: To date, there are no immunological data on COVID-19 heterologous vaccination schedules in humans. This study evaluated the immunogenicity and reactogenicity of administering BNT162b2 as a second dose in individuals primed with ChAdOx1-S. The results showed that BNT162b2 induced a robust immune response in individuals prime vaccinated with ChAdOx1-S, with an acceptable and manageable reactogenicity profile.

LANCET (2021)

Add to Collection

Letter Infectious Diseases

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2

Matthias Tenbusch et al.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Joana Barros-Martins et al.

Summary: A study found that booster vaccination with BNT162b2 in healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19 elicited more neutralizing antibodies and higher frequencies of virus-specific T cells. Additionally, BNT162b2 induced high titers of neutralizing antibodies against variants of concern, such as B.1.1.7, B.1.351, and P.1.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Moriah Bergwerk et al.

Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

News Item Multidisciplinary Sciences

COVID-19 Can immune responses predict which vaccines work best?

Jon Cohen

SCIENCE (2021)

Add to Collection

Article Critical Care Medicine

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

David Hillus et al.

Summary: This study evaluated the reactogenicity and immunogenicity of homologous and heterologous COVID-19 vaccinations, with results showing that heterologous immunization has good immunogenicity and tolerability.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses

Muhammad Adnan Shereen et al.

JOURNAL OF ADVANCED RESEARCH (2020)

Add to Collection

Review Infectious Diseases

Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis

Laura M. Nic Lochlainn et al.

LANCET INFECTIOUS DISEASES (2019)

Add to Collection

Article Health Care Sciences & Services

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

Gordon Guyatt et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)

Add to Collection

Review Medicine, General & Internal

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Alessandro Liberati et al.

BMJ-BRITISH MEDICAL JOURNAL (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.